Description:
What is the Size of the IVD Market in 2021?
What Major Trends are Affecting the Market in 2021?
Diagnostic test products have never been more crucial. This report, IVD Market Brief Update, 2021, is an updated analysis of the in vitro diagnostics (IVD) market from Kalorama Information, reflecting the latest data as of Q4 2021. It includes market sizing for several key categories within the IVD sector.
The demand for diagnostic testing and the adoption of current and new technologies continue to drive growth across most areas of the IVD market. New products, shifts in global health spending, regulatory changes in major markets, and disease trends contribute to the evolving market landscape. Several growing segments have captured industry attention, including next-generation sequencing (NGS), cancer testing, and companion diagnostics technologies. Immunochemistry, point-of-care (POC) testing, and molecular diagnostics are also segments of significant market interest and are expected to play a major role in the future of IVD. The IVD market remains dynamic, consistently showcasing innovations.
Kalorama Information provides a comprehensive overview of the IVD market and its rapidly changing landscape. While COVID-19 has positively impacted the IVD diagnostics market, forecasting has become challenging due to the pandemic’s uncertain trajectory. However, Kalorama Information stands out for its in-depth market insights, thanks to the extensive experience of its authors and the company’s commitment to delivering the most accurate data available.
Explore this detailed report to understand the size, trends, and future directions of the IVD market in 2021, and stay ahead in this rapidly evolving industry.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Global In Vitro Diagnostic Sales, by Product Market, 2021 ($ million)
| Product | 2021 | %Mkt |
| Chemistry | $XX Million | XX% |
| Immunoassays | $XX Million | XX% |
| Infectious disease | $XX Million | XX% |
| Other immunos | $XX Million | XX% |
| Blood bank screening | $XX Million | XX% |
| Drugs of Abuse | $XX Million | XX% |
| Diabetes HbA1c, lab | $XX Million | XX% |
| Hematology – Core Lab | $XX Million | XX% |
| Microbiology (ID/AST) | $XX Million | XX% |
| Microbiology (molecular) | $XX Million | XX% |
| Microbiology – Mass Spectrometry | $XX Million | XX% |
| Coagulation (PT/INR) | $XX Million | XX% |
| Coagulation, molecular | $XX Million | XX% |
| D-dimer | $XX Million | XX% |
| Histology/cytology | $XX Million | XX% |
| HPV, molecular | $XX Million | XX% |
| Nucleic acid assays/genetic tests | $XX Million | XX% |
| Blood grouping/typing | $XX Million | XX% |
| Blood bank molecular – NAT Screens | $XX Million | XX% |
| Circulating tumor cells | $XX Million | XX% |
| POC, OTC diabetes | $XX Million | XX% |
| POC, OTC other | $XX Million | XX% |
| POC, professional/hospital | $XX Million | XX% |
| Mass Spectrometry | $XX Million | XX% |
| Other (transplant testing, other) | $XX Million | XX% |
| IVD Market Total | $XX Million | XX% |
Source: Kalorama Information
